Korean J Gastroenterol.  2016 Jul;68(1):10-15. 10.4166/kjg.2016.68.1.10.

Effect of Proton Pump Inhibitors in Bronchiectatic Patients with Gastroesophageal Reflux Disease

• Ahn B
• Lee DH
• Lee CM
• Hwang JJ
• Yoon H
• Shin CM
• Park YS
• Kim N

• KMID: 2344486
• DOI: http://doi.org/10.4166/kjg.2016.68.1.10

Abstract

BACKGROUND/AIMS
Bronchiectasis is aggravated by gastroesophageal reflux disease (GERD) owing to micro aspiration. Some researchers note the effect of antireflux surgery in bronchiectasis with GERD. However, few have investigated the effects of medical antireflux therapy. We investigated the effect of proton pump inhibitors (PPIs) in bronchiectasis with GERD.
METHODS
From March 2003 to May 2015, the clinical records of patients who had bronchiectasis with GERD were reviewed. Patients underwent an initial pulmonary function test (PFT) and chest computed tomography when diagnosed with bronchiectasis. One group with typical GERD symptoms was treated with PPIs, while the other group was not. Both groups underwent PFTs within six months after completing PPI therapy. Population characteristics and associations were compared between the groups.
RESULTS
Two hundred and fifty-seven patients (124 male, 133 female; mean age 67.6±10.0 years) were included. There were no significant differences between the groups in terms of forced vital capacity (FVC; p=0.239), forced expiratory volume in one second (FEV1; p=0.555), or FEV1/FVC (p=0.374) after PPI therapy. However, there were significant improvements in FVC (p=0.002) and FEV1 (p=0.006) in patients with high BMI in the PPI treatment group.
CONCLUSIONS
PPIs have no effect on the pulmonary function in patients with bronchiectasis and GERD. However, PPIs were noted to produce improvements in lung function in patients with bronchiectasis and high BMI.

Keyword

Bronchiectasis; Gastroesophageal reflux; Proton pump inhibitors

MeSH Terms

Bronchiectasis
Female
Forced Expiratory Volume
Gastroesophageal Reflux*
Humans
Lung
Male
Population Characteristics
Proton Pump Inhibitors*
Proton Pumps*
Protons*
Respiratory Function Tests
Thorax
Vital Capacity
Proton Pump Inhibitors
Proton Pumps
Protons

Figure

• 

  Fig. 1. Severity of obesity and lung function in patients with bronchiectasis and gastroesophageal reflux disease. (A) Differences in lung function between before and after antireflux treatment in the proton pump inhibitor (PPI) treatment group. (B) Differences in lung function between before and after antireflux treatment in the non-PPI treatment group. *p<0.05. FVC, forced vital capacity; FEV1, forced expiratory volume in 1 second; diff., difference in lung function parameters before and after anti-reflux treatment. Underweight: BMI <18.5; normal: BMI ≥18.5, <23; overweight: ≥23, <25; mildly obese: ≥25, <30; moderately obese: ≥30, <35; severely obese: BMI ≥35.

Reference

References

1. Ilowite J, Spiegler P, Chawla S. Bronchiectasis: new findings in the pathogenesis and treatment of this disease. Curr Opin Infect Dis. 2008; 21:163–167.

2. Weycker D, Edelsberg J, Oster G, Tino G. Prevalence and economic burden of bronchiectasis. Clin Pulm Med. 2005; 12:205–209.

3. Chang AB, Bilton D. Exacerbations in cystic fibrosis:4–Non-cystic fibrosis bronchiectasis. Thorax. 2008; 63:269–276.

4. Tsang KW, Lam WK, Kwok E, et al. Helicobacter pylori and upper gastrointestinal symptoms in bronchiectasis. Eur Respir J. 1999; 14:1345–1350.

5. Kim JH. Are proton pump inhibitors effective in asthmatics with gastroesophageal reflux disease? Korean J Gastroenterol. 2011; 58:169–170.

6. Lee AL, Button BM, Denehy L, et al. Proximal and distal gas-tro-oesophageal reflux in chronic obstructive pulmonary disease and bronchiectasis. Respirology. 2014; 19:211–217.

7. Lee AL, Button BM, Denehy L, Wilson JW. Gastro-oesophageal reflux in noncystic fibrosis bronchiectasis. Pulm Med. 2011; 2011:395020.

8. Ozaydin I, Annakkaya AN, Ozaydin C, Aydın M. Effects of cruro-raphy and laparoscopic Nissen fundoplication procedures on pulmonary function tests in gastroesophageal reflux patients. Int J Clin Exp Med. 2014; 7:431–434.

9. Hu ZW, Wang ZG, Zhang Y, et al. Gastroesophageal reflux in bronchiectasis and the effect of anti-reflux treatment. BMC Pulm Med. 2013; 13:34.

10. Vakil N, van Zanten SV, Kahrilas P, Dent J, Jones R. Global Consensus Group. The montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. Am J Gastroenterol. 2006; 101:1900–1920. quiz 1943.

11. Sweet MP, Patti MG, Hoopes C, Hays SR, Golden JA. Gastro-oesophageal reflux and aspiration in patients with advanced lung disease. Thorax. 2009; 64:167–173.

12. Schan CA, Harding SM, Haile JM, Bradley LA, Richter JE. Gastroesophageal reflux-induced bronchoconstriction. An intra-esophageal acid infusion study using state-of-the-art technology. Chest. 1994; 106:731–737.

13. Sweet MP, Herbella FA, Leard L, et al. The prevalence of distal and proximal gastroesophageal reflux in patients awaiting lung transplantation. Ann Surg. 2006; 244:491–497.

14. Tsang KW, Lam SK, Lam WK, et al. High seroprevalence of Helicobacter pylori in active bronchiectasis. Am J Respir Crit Care Med. 1998; 158:1047–1051.

15. Mégraud F. Toxic factors of Helicobacter pylori. Eur J Gastroenterol Hepatol. 1994; 6(Suppl 1):S5–S10.

16. Goodwin CS, Armstrong JA, Marshall BJ. Campylobacter pyloridis, gastritis, and peptic ulceration. J Clin Pathol. 1986; 39:353–365.

17. Pasteur MC, Helliwell SM, Houghton SJ, et al. An investigation into causative factors in patients with bronchiectasis. Am J Respir Crit Care Med. 2000; 162:1277–1284.

18. Shah SL, Lacy BE, DiBaise JK, Vela MF, Crowell MD. The impact of obesity on oesophageal acid exposure time on and off proton pump inhibitor therapy. Aliment Pharmacol Ther. 2015; 42:1093–1100.